Gut Barrier, Microbial Metabolites, and Immune Homeostasis in Autoimmune Hepatitis: From Molecular Mechanisms to Strategies DOI Creative Commons

Xintong Zhang,

Lin‐Yan Wan, Yujiao Zheng

и другие.

Frontiers in Bioscience-Landmark, Год журнала: 2025, Номер 30(5)

Опубликована: Апрель 30, 2025

Autoimmune hepatitis (AIH) is a chronic immune-mediated inflammatory liver disease characterized by recurring immune-triggered hepatic injury. While scientists have yet to fully elucidate the precise triggers of AIH, contemporary research indicates that both gut microbiota and their metabolic products significantly influence AIH progression. These factors contribute multiple mechanisms, including compromised intestinal barrier function, altered microbial metabolite trafficking, disrupted immune balance, leading responses. This review begins exploring populations byproducts linked AIH. It highlights how flora compromises defenses, enables bacterial migration from tissue, induces Research validates microbes, such as short-chain fatty acids (SCFAs), bile (BAs), specific amino (glutamine, cysteine, tryptophan, branched-chain variants, among others), interact with cell populations. interactions, coupled modifications, Our identifies promising treatment strategies, use probiotic supplementation, engineered prebiotic compounds, transfer procedures, medications targeting microorganisms byproducts. approaches could potentially reduce damage, offering potential new avenues for management.

Язык: Английский

Role of the intestinal microbiome and its therapeutic intervention in cardiovascular disorder DOI Creative Commons

Ameer Luqman,

Adil Hassan,

Mehtab Ullah

и другие.

Frontiers in Immunology, Год журнала: 2024, Номер 15

Опубликована: Янв. 26, 2024

The gut microbiome is a heterogeneous population of microbes comprising viruses, bacteria, fungi, and protozoa. Such essential for sustaining host equilibrium, its impact on human health can be altered by variety factors such as external variables, social behavior, age, nutrition, genetics. Gut microbes’ imbalances are related to chronic diseases including cancer, obesity, digestive disorders. Globally, recent findings show that intestinal have significant role in the formation cardiovascular disease (CVD), which still primary cause fatalities. Atherosclerosis, hypertension, diabetes, inflammation, some inherited variables all risk variables. However, studies found correlations between metabolism, flora, dietary intake. Variations diversity changes their activity thought influence CVD etiology. Furthermore, microbiota acts an endocrine organ, producing bioactive metabolites TMA (trimethylamine)/TMAO (trimethylamine N-oxide), SCFA (short-chain fatty acids), bile acids, substantial wellness multiple mechanisms. purpose this overview compile current evidence highlighting intricate links microbiota, metabolites, development CVD. It focuses how dysbiosis promotes heart failure, atherosclerosis. This review explores normal physiology potential techniques targeting bacteria treatment using various microbial metabolites. also examines significance treatment, supplements, prebiotics, probiotics, antibiotic therapies, fecal transplantation, innovative approach management As result, metabolic pathways become increasingly attractive targets intervention.

Язык: Английский

Процитировано

42
Microbiome Dynamics: A Paradigm Shift in Combatting Infectious Diseases DOI Open Access
Mohamed Kamel,

Sami Aleya,

Majed Alsubih

и другие.

Journal of Personalized Medicine, Год журнала: 2024, Номер 14(2), С. 217 - 217

Опубликована: Фев. 18, 2024

Infectious diseases have long posed a significant threat to global health and require constant innovation in treatment approaches. However, recent groundbreaking research has shed light on previously overlooked player the pathogenesis of disease-the human microbiome. This review article addresses intricate relationship between microbiome infectious unravels its role as crucial mediator host-pathogen interactions. We explore remarkable potential harnessing this dynamic ecosystem develop innovative strategies that could revolutionize management diseases. By exploring latest advances emerging trends, aims provide new perspective combating by targeting

Язык: Английский

Процитировано

26
Microbiome as a biomarker and therapeutic target in pancreatic cancer DOI Creative Commons
Ghazaleh Pourali, Danial Kazemi,

Amir Shayan Chadeganipour

и другие.

BMC Microbiology, Год журнала: 2024, Номер 24(1)

Опубликована: Янв. 5, 2024

Abstract Studying the effects of microbiome on development different types cancer has recently received increasing research attention. In this context, microbial content organs gastrointestinal tract been proposed to play a potential role in pancreatic (PC). Proposed mechanisms for pathogenesis PC include persistent inflammation caused by microbiota leading an impairment antitumor immune surveillance and altered cellular processes tumor microenvironment. The limited available diagnostic markers that can currently be used screening suggest importance composition as non-invasive biomarker clinical settings. Samples including saliva, stool, blood analyzed 16 s rRNA sequencing determine relative abundance specific bacteria. Studies have shown potentially beneficial prebiotics, probiotics, antibiotics, fecal transplantation, bacteriophage therapy altering diversity, subsequently improving treatment outcomes. review, we summarize impact PC, these microorganisms might biomarkers diagnosis determining prognosis patients. We also discuss novel methods being minimize or prevent progression dysbiosis modulating composition. Emerging evidence is supportive applying findings improve current therapeutic strategies employed PC.

Язык: Английский

Процитировано

22
A systematic framework for understanding the microbiome in human health and disease: from basic principles to clinical translation DOI Creative Commons

Ziqi Ma,

Tao Zuo, Norbert Frey

и другие.

Signal Transduction and Targeted Therapy, Год журнала: 2024, Номер 9(1)

Опубликована: Сен. 23, 2024

Язык: Английский

Процитировано

20
The Networked Interaction between Probiotics and Intestine in Health and Disease: A Promising Success Story DOI Creative Commons

Maria Skoufou,

Christina Tsigalou, Stergios Vradelis

и другие.

Microorganisms, Год журнала: 2024, Номер 12(1), С. 194 - 194

Опубликована: Янв. 18, 2024

Probiotics are known to promote human health either precautionary in healthy individuals or therapeutically patients suffering from certain ailments. Although this knowledge was empirical past tomes, modern science has already verified it and expanded new limits. These microorganisms can be found nature various foods such as dairy products supplements formulated for clinical preventive use. The current review examines the different mechanisms of action probiotic strains how they interact with organism host. Emphasis is put on therapeutic use these beneficial conditions gastrointestinal tract. Diseases tract particularly any malfunction inflammation intestines seriously compromise whole organism. interaction between host’s microbiota alleviate signs symptoms while some cases, due course, intervene underlying pathology. Various safety issues probiotics also discussed.

Язык: Английский

Процитировано

15
Microbiota and immune dynamics in rheumatoid arthritis: Mechanisms and therapeutic potential DOI
Jiayang Jin,

Xuanlin Cai,

Peishi Rao

и другие.

Best Practice & Research Clinical Rheumatology, Год журнала: 2025, Номер unknown, С. 102035 - 102035

Опубликована: Янв. 1, 2025

Язык: Английский

Процитировано

1
Microbiome Integrity Enhances the Efficacy and Safety of Anticancer Drug DOI Creative Commons
Alice Njolke Mafe, Dietrich Büsselberg

Biomedicines, Год журнала: 2025, Номер 13(2), С. 422 - 422

Опубликована: Фев. 10, 2025

The intricate relationship between anticancer drugs and the gut microbiome influences cancer treatment outcomes. This review paper focuses on role of integrity in enhancing efficacy safety drug therapy, emphasizing pharmacokinetic interactions microbiota. It explores how disruptions to composition, or dysbiosis, can alter metabolism, immune responses, side effects. By examining mechanisms disruption caused by drugs, this highlights specific case studies like cyclophosphamide, 5-fluorouracil, irinotecan, their impact microbial diversity clinical also discusses microbiome-targeted strategies, including prebiotics, probiotics, postbiotics, fecal microbiota transplantation (FMT), as promising interventions enhance treatment. Furthermore, potential profiling personalizing therapy integrating these into practice is explored. Finally, proposes future research directions, developing novel biomarkers a deeper comprehension drug-microbiome interactions, respond current gaps knowledge improve patient outcomes care.

Язык: Английский

Процитировано

1
The Complex Role of Gut Microbiota in Systemic Lupus Erythematosus and Lupus Nephritis: From Pathogenetic Factor to Therapeutic Target DOI Creative Commons
E Parodi,

M. Novi,

Paolo Bottino

и другие.

Microorganisms, Год журнала: 2025, Номер 13(2), С. 445 - 445

Опубликована: Фев. 18, 2025

The role of gut microbiota (GM) and intestinal dysbiosis in triggering the onset and/or modulating severity progression lupus nephritis (LN) has been object intense research over last few years. Some alterations at phyla level, such as abundance Proteobacteria reduction Firmicutes/Bacteroidetes (F/B) ratio α-diversity have consistently reported systemic erythematosus (SLE), whereas a more specific ascribed to some species (Bacteroides thetaiotaomicron Ruminococcus gnavus) LN. Underlying mechanisms include microbial translocation through "leaky gut" subsequent molecular mimicry, immune dysregulation (alteration IFNγ levels balance between Treg Th17 subsets), epigenetic interactions. Levels bacterial metabolites, butyrate other short-chain fatty acids (SCFAs), appear play key Beyond components GM, virome mycobiome are also increasingly recognized important players modulation an response. On hand, microbiota-based therapy appears promising includes diet, prebiotics, probiotics, symbiotics, fecal transplantation (FMT). could correct critical alterations, F/B Treg/Th17 imbalance, blunt production autoantibodies renal damage. Despite current limits, GM is emerging powerful environmental factor that be harnessed interfere with leading SLE, preventing flares organ damage, including aim this review provide state-of-the-art analysis SLE LN on one while exploring possible therapeutic manipulation control disease hand.

Язык: Английский

Процитировано

1
Current landscape of fecal microbiota transplantation in treating depression DOI Creative Commons
Qi Zhang,

Yajun Bi,

Boyu Zhang

и другие.

Frontiers in Immunology, Год журнала: 2024, Номер 15

Опубликована: Июнь 25, 2024

Depression, projected to be the predominant contributor global disease burden, is a complex condition with diverse symptoms including mood disturbances and cognitive impairments. Traditional treatments such as medication psychotherapy often fall short, prompting pursuit of alternative interventions. Recent research has highlighted significant role gut microbiota in mental health, influencing emotional neural regulation. Fecal transplantation (FMT), infusion fecal matter from healthy donor into patient, emerges promising strategy ameliorate depressive by restoring microbial balance. The microbial-gut-brain (MGB) axis represents critical pathway through which potentially rectify dysbiosis modulate neuropsychiatric outcomes. Preclinical studies reveal that FMT can enhance neurochemicals reduce inflammatory markers, thereby alleviating behaviors. Moreover, shown promise clinical settings, improving gastrointestinal overall quality life patients depression. review highlights gut-brain depression need for further validate long-term safety efficacy FMT, identify specific therapeutic strains, develop targeted modulation strategies. Advancing our understanding could revolutionize treatment, shifting paradigm toward microbiome-targeting therapies.

Язык: Английский

Процитировано

7
Revolutionizing Gastrointestinal Disorder Management: Cutting-Edge Advances and Future Prospects DOI Open Access

C. Raman Suri,

Babita Pande, Tarun Sahu

и другие.

Journal of Clinical Medicine, Год журнала: 2024, Номер 13(13), С. 3977 - 3977

Опубликована: Июль 8, 2024

In recent years, remarkable strides have been made in the management of gastrointestinal disorders, transforming landscape patient care and outcomes. This article explores latest breakthroughs field, encompassing innovative diagnostic techniques, personalized treatment approaches, novel therapeutic interventions. Additionally, this emphasizes use precision medicine tailored to individual genetic microbiome profiles, application artificial intelligence disease prediction monitoring. review highlights dynamic progress managing conditions such as inflammatory bowel disease, gastroesophageal reflux irritable syndrome, cancers. By delving into these advancements, we offer a glimpse promising future gastroenterology, where multidisciplinary collaborations cutting-edge technologies converge provide more effective, patient-centric solutions for individuals grappling with disorders.

Язык: Английский

Процитировано

6